Help Find A Cure For ALPHA-1!

September 2008

Kamada Successfully Completes Phase II Trial with Aerosolized AAT in Cystic Fibrosis Patients

August 2008

Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha1-Antitrypsin (AAT) From the European Commission

July 2008

Kamada Is Pursuing US Market With Its Aerosolized AAT

October 2007

Study Demonstrates Aerosolized Prolastin® Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs

September 2007

Kamada Trial Now Enrolling

February 2007

Bird Flu and the Alpha-1 Community

June 2006

Delay in Diagnosis of Alpha-1 Antitrypsin Deficiency

October 2005

Trends in the Diagnosis of Symptomatic Patients With Alpha-1 Antitrypsyn Deficiency Between 1968 and 2003

September 2005

AlphaNet Makes “Big Fat Reference Guide” Available on New Website

May 2005

Announcing the Launch of Talecris Biotherapeutics: Combining a Proud History of Patient Care with a Bold New Vision

April 2005

National Education Conference Rescheduled

February 2005

Bayer Divestiture Press Release

December 2004

Bayer AG announces it is initiating a process to divest its plasma business

October 2003

Harbaugh Survey II Press Release

June 2003

Harbaugh Survey II Results

April 2003

Severe Acute Respiratory Syndrome (SARS) and Alpha-1

April 2003

AlphaNet Supports Alpha-1 Association to Ensure Continued Community Service

March 2003

Bayer Announces Additional Prolastin® Safety Measures

February 2003

Bayer and Aventis Discontinue Joint Venture Discussions

January 2003